who knows, but something closer to approved product (or even approved). But something that is not performing due to access or whatever. Or perhaps not buy something outright, but add-on something and take a clip from it being on the platform.
This is why they keep saying we are looking for bolt-on acquisitions and they said this in the letter from Boreham report
" Dr McKibbon says could be used as a springboard for an acquired therapy." “In future we could take an underperforming drug and it would be five times as valuable in our hands.”
How long did it take from buying sofdra till approval - was it a year or two? - I can't remember. But even that was close to approval and ti still took about 2 years.
I don't think they are looking for that again. At least they seem to be saying otherwise.
BOT Price at posting:
30.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)